Bielack, S. S., Cox, M. C., Nathrath, M., Apel, K., Blattmann, C., Holl, T., . . . von Kalle, T. (2019). Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion. Ann Oncol.
Stile di citazione ChicagoBielack, S S., et al. "Rapid, Complete and Sustained Tumour Response to the TRK Inhibitor Larotrectinib in an Infant With Recurrent, Chemotherapy-refractory Infantile Fibrosarcoma Carrying the Characteristic ETV6-NTRK3 Gene Fusion." Ann Oncol 2019.
Citazione MLABielack, S S., et al. "Rapid, Complete and Sustained Tumour Response to the TRK Inhibitor Larotrectinib in an Infant With Recurrent, Chemotherapy-refractory Infantile Fibrosarcoma Carrying the Characteristic ETV6-NTRK3 Gene Fusion." Ann Oncol 2019.